Literature DB >> 7751686

Epstein-Barr virus coinfection and recombination in non-human immunodeficiency virus-associated oral hairy leukoplakia.

D M Walling1, N M Clark, D M Markovitz, T S Frank, D K Braun, E Eisenberg, D J Krutchkoff, D H Felix, N Raab-Traub.   

Abstract

Human immunodeficiency virus-associated oral hairy leukoplakia (HLP) is characterized by coinfection with multiple types and strains of Epstein-Barr virus (EBV) and recombination within the EBV genome. HIV-seronegative immunosuppressed and immunocompetent patients with HLP were examined to determine the pathogenic contribution of EBV coinfection and recombination to the development of HLP. Multiple coinfecting EBV strains were detected in both HLP specimens and peripheral blood lymphocytes (PBL) of HIV-seronegative persons with HLP. One specific EBV strain was detected in HLP specimens from 3 of 4 patients. Also, viral recombination during productive replication within HLP generated variants of the latent membrane protein-1 (LMP-1) and nuclear antigen-2 (EBNA-2) genes. Some variants were also detected within PBL. Thus, EBV coinfection and recombination are consistent findings in persons with HLP regardless of immune status. Virally mediated determinants may be important features of EBV pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7751686     DOI: 10.1093/infdis/171.5.1122

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

Review 1.  Epstein-Barr virus in the pathogenesis of oral cancers.

Authors:  J T Guidry; C E Birdwell; R S Scott
Journal:  Oral Dis       Date:  2017-04-18       Impact factor: 3.511

2.  Epidemiology of infection with Epstein-Barr virus types 1 and 2: lessons from the study of a T-cell-immunocompromised hemophilic cohort.

Authors:  Q Y Yao; D S Croom-Carter; R J Tierney; G Habeshaw; J T Wilde; F G Hill; C Conlon; A B Rickinson
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 3.  The Long and Complicated Relationship between Epstein-Barr Virus and Epithelial Cells.

Authors:  Lindsey M Hutt-Fletcher
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

4.  In vitro selection of RNA ligands for the ribosomal L22 protein associated with Epstein-Barr virus-expressed RNA by using randomized and cDNA-derived RNA libraries.

Authors:  M Dobbelstein; T Shenk
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

5.  Epstein-Barr virus induction of recombinase-activating genes RAG1 and RAG2.

Authors:  S K Srinivas; J W Sixbey
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

6.  Isolation of intertypic recombinants of Epstein-Barr virus from T-cell-immunocompromised individuals.

Authors:  Q Y Yao; R J Tierney; D Croom-Carter; G M Cooper; C J Ellis; M Rowe; A B Rickinson
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

7.  Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individuals.

Authors:  Q Y Yao; R J Tierney; D Croom-Carter; D Dukers; G M Cooper; C J Ellis; M Rowe; A B Rickinson
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

8.  Identification of Epstein-Barr virus strain variants in hairy leukoplakia and peripheral blood by use of a heteroduplex tracking assay.

Authors:  Diane Sitki-Green; Rachel H Edwards; Jennifer Webster-Cyriaque; Nancy Raab-Traub
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Virologic Diagnosis, Viral Monitoring, and Treatment of Epstein-Barr Virus Infectious Mononucleosis.

Authors:  Hal B. Jenson
Journal:  Curr Infect Dis Rep       Date:  2004-06       Impact factor: 3.725

10.  An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link.

Authors:  Gemma L Kelly; Heather M Long; Julianna Stylianou; Wendy A Thomas; Alison Leese; Andrew I Bell; Georg W Bornkamm; Josef Mautner; Alan B Rickinson; Martin Rowe
Journal:  PLoS Pathog       Date:  2009-03-13       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.